EGFR and non-small cell lung carcinoma: One study reported that 11 relapsed/refractory NSCLC patients with >50% epidermal growth factor receptor (EGFR) positive in lung tissue immunohistochemistry (IHC) at stage IIB or higher were treated with CAR-T cells targeting at EGFR in combination with chemotherapy pre-conditions.26